Booster vaccination of toddlers with reduced antigen content diphtheria-tetanus-acellular pertussis vaccine

Vaccine

Volumn 27, Issue 18, 2009, Pages 2410-2413

  Nolan, Terry ^a   Ruff, Tilman A ^b   Lambert, Stephen B ^a   Buttery, Jim ^a   O'Grady, Kerry Ann ^a   Streeton, Catherine ^c   Hoet, Bernard ^c   Bock, Hans L ^c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b GLAXOSMITHKLINE   (Australia)

^c GSK   (Belgium)

Author keywords

Acellular pertussis vaccine; Booster; Vaccination

Indexed keywords

DIPHTHERIA ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEPATITIS A VACCINE;

ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIPHTHERIA; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INJECTION SITE SWELLING; IRRITABILITY; MALE; PERTUSSIS; PRESCHOOL CHILD; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SIDE EFFECT; SINGLE BLIND PROCEDURE; SKIN REDNESS; TETANUS;

ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; DOUBLE-BLIND METHOD; HUMANS; IMMUNIZATION, SECONDARY; INFANT; SINGLE-BLIND METHOD;

EID: 62949195584     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.02.065     Document Type: Article

References (17)

1. Jackson L.A., Carste B.A., Malais D., and Froeschle J. Retrospective population-based assessment of medically attended injection site reactions, seizures, allergic responses and febrile episodes after acellular pertussis vaccine combined with diphtheria and tetanus toxoids. Pediatr Infect Dis J 21 8 (2002) 781-786
2. Tozzi A.E., Anemona A., Stefanelli P., Salmaso S., Ciofi degli Atti M.L., Mastrantonio P., et al. Reactogenicity and immunogenicity at preschool age of a booster dose of two three-component diphtheria-tetanus-acellular pertussis vaccines in children primed in infancy with acellular vaccines. Pediatrics 107 2 (2001) e25
3. Liese J.G., Stojanov S., Zink T.H., Froeschle J., Klepadlo R., Kronwitter A., et al. Safety and immunogenicity of Biken acellular pertussis vaccine in combination with diphtheria and tetanus toxoid as a fifth dose at four to six years of age. Munich Vaccine Study Group. Pediatr Infect Dis J 20 10 (2001) 981-988
4. Rennels M.B., Deloria M.A., Pichichero M.E., Losonsky G.A., Englund J.A., Meade B.D., et al. Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines. Pediatrics 105 1 (2000) e12
5. Gold M.S., Noonan S., Osbourn M., Precepa S., and Kempe A.E. Local reactions after the fourth dose of acellular pertussis vaccine in South Australia. Med J Aust 179 4 (2003) 191-194
6. Wassilak A.G.F., Roper M.H., Murphy T.V., and Orenstein W.A. In: Plotkin S.A., and Orenstein W.A. (Eds). Tetanus toxoid. Vaccines. 4th ed. (2004), WB Saunders Company, Philadelphia 745-781
7. The Australian immunisation handbook. 8th ed. Canberra: NHMRC;September 2003:210.
8. Pediatric guidelines. NKF K/DOQI guidelines 2000. Available at http://www.kidney.org/professionals/KDOQI/guidelines_updates/nut_appx1p. html. Accessed on 26.02.08.
9. Saenger R., Behre U., Krause K.H., Loch H.P., Soemantri P., Herrmann D., et al. Booster vaccination and 1-year follow-up of 4-8-year-old children with a reduced-antigen-content dTpa-IPV vaccine. Eur J Pediatr 166 12 (2007) 1229-1236
10. Collins C.L., Salt P., McCarthy N., Chantler T., Lane L., Hemme F., et al. Immunogenicity and safety of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine as a pre-school booster in UK children. Vaccine 22 31-32 (2004) 4262-4269
11. Meyer C.U., Habermehl P., Knuf M., Hoet B., Wolter J., and Zepp F. Immunogenicity and reactogenicity of acellular pertussis booster vaccines in children: Standard pediatric versus a reduced-antigen content formulation. Hum vaccin 4 3 (2008) 30-36
12. Cheuvart B., Burgess M., Zepp F., Mertsola J., Wolter J., and Schuerman L. Anti-diphtheria antibody seroprotection rates are similar 10 years after vaccination with dTpa or DTPa using a mathematical model. Vaccine 23 3 (2004) 336-342
13. Knuf M., Habermehl P., Faber J., Bock H.L., Sanger R., Bogaerts H., et al. Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life. Vaccine 24 27-28 (2006) 5627-5636
14. Vergara R., Tregnaghi M., Ussher J., Navarro S., Ruttimann R., Potin M., et al. Reduced-antigen-content-diphtheria-tetanus-acellular-pertussis and inactivated polio vaccine as a booster for adolescents 10 to 14 years of age. Eur J Pediatr 164 6 (2005) 377-382
15. National Health & Medical Research Council. The Australian immunisation handbook. 8th ed. 2003 (September 2003), NHMRC, Canberra
16. Salmaso S., Mastrantonio P., Tozzi A.E., Stefanelli P., Anemona A., Ciofi degli Atti M.L., et al. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Pediatrics 108 5 (2001) e81
17. 197 conjugate vaccine on diphtheria immunity and reactogenicity in pre-school aged children. Vaccine 21 (2003) 2573-2579